M&T Bank Corp Takes Position in Roivant Sciences Ltd. $ROIV

Key Points

• M&T Bank Corp bought a new stake of 420,384 shares of Roivant Sciences (NASDAQ:ROIV) in Q4, valued at about $9.12 million and representing roughly 0.06% of the company.
• Insiders have been net sellers: CEOs Eric Venker and Matthew Gline sold 200,000 and 289,774 shares respectively, and insiders sold 5,085,398 shares (~$139.2M) in the past three months; insiders now own 10.8% of the stock.
• Wall Street sentiment is broadly positive with a "Moderate Buy" consensus and a $30.55 average target; ROIV trades near $27.41, has a $19.62 billion market cap and a 52-week range of $10.58–$30.33.

M&T Bank Corp bought a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 420,384 shares of the company's stock, valued at approximately $9,122,000. M&T Bank Corp owned about 0.06% of Roivant Sciences as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Goldman Sachs Group Inc. lifted its position in Roivant Sciences by 15.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company's stock worth $24,553,000 after buying an additional 324,764 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Roivant Sciences by 1.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company's stock valued at $24,678,000 after acquiring an additional 34,341 shares during the last quarter. American Century Companies Inc. raised its stake in shares of Roivant Sciences by 1.9% in the second quarter. American Century Companies Inc. now owns 89,625 shares of the company's stock valued at $1,010,000 after acquiring an additional 1,689 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Roivant Sciences by 149.9% in the second quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company's stock valued at $129,000 after acquiring an additional 6,879 shares during the period. Finally, Amundi lifted its holdings in shares of Roivant Sciences by 1.4% in the 2nd quarter. Amundi now owns 404,436 shares of the company's stock worth $4,437,000 after acquiring an additional 5,707 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.

Insider Activity

In related news, CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $29.59, for a total transaction of $5,918,000.00. Following the completion of the sale, the chief executive officer directly owned 1,647,546 shares of the company's stock, valued at approximately $48,750,886.14. This trade represents a 10.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew Gline sold 289,774 shares of the firm's stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $29.16, for a total value of $8,449,809.84. Following the sale, the chief executive officer directly owned 16,736,116 shares of the company's stock, valued at $488,025,142.56. This represents a 1.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 5,085,398 shares of company stock worth $139,215,946 in the last three months. Corporate insiders own 10.80% of the company's stock.

Roivant Sciences Stock Performance

Shares of ROIV stock opened at $27.41 on Friday. Roivant Sciences Ltd. has a 52-week low of $10.58 and a 52-week high of $30.33. The firm has a market capitalization of $19.62 billion, a P/E ratio of -23.43 and a beta of 1.20. The stock has a 50 day moving average price of $28.24 and a 200 day moving average price of $23.57.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ROIV. Weiss Ratings cut shares of Roivant Sciences from a "hold (c-)" rating to a "sell (d)" rating in a research note on Monday, February 9th. Piper Sandler upped their price target on shares of Roivant Sciences from $22.00 to $40.00 and gave the company an "overweight" rating in a report on Thursday, April 16th. Jefferies Financial Group reiterated a "buy" rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. TD Cowen reiterated a "buy" rating on shares of Roivant Sciences in a report on Wednesday, March 4th. Finally, Citigroup upped their price target on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a "buy" rating in a report on Tuesday, February 10th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $30.55.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.